Total trials
4,446
Capped at 5,000
Active
1,085
Phase 3
197
Total enrollment
1,627,838
Pipeline matrix
Showing 40 of 263 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Calcium Hydroxide | — | — | 12 | ||||
| Normal (0.9%) saline | — | — | — | — | — | 2 | |
| Bupivacaine | — | 21 | |||||
| Dexamethasone | — | — | 10 | ||||
| Norepinephrine | — | — | — | 9 | |||
| Control group | — | — | — | — | 6 | ||
| intravenous tranexamic acid | — | — | — | — | 5 | ||
| Lactoferrin | — | — | — | 4 | |||
| Methotrexate | — | — | — | 4 | |||
| Metformin Hydrochloride 500 MG | — | — | — | — | 2 | ||
| Ferrous Sulfate | — | — | — | — | — | 2 | |
| oral Iron | — | — | — | — | — | 1 | |
| lactoferrin and oral iron | — | — | — | — | — | 1 | |
| Egyptian MTA | — | — | — | — | — | 1 | |
| Lidocaine group | — | — | — | — | — | 1 | |
| Magnesium group | — | — | — | — | — | 1 | |
| Hypertonic 3% saline | — | — | — | — | — | 1 | |
| Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety | — | — | — | — | — | 1 | |
| Acetyl cysteine | — | — | — | — | — | 1 | |
| nebulized tranexamic acid | — | — | — | — | — | 1 | |
| Acetazolamide | — | — | — | — | — | 1 | |
| Metolazone | — | — | — | — | — | 1 | |
| IV Loop Diuretics | — | — | — | — | — | 1 | |
| Menaquinone | — | — | — | — | — | 1 | |
| Antivet | — | — | — | — | — | 1 | |
| opalustre | — | — | — | — | — | 1 | |
| Oral ondansetron strips | — | — | — | — | — | 1 | |
| Lidocaine-Prilocaine Topical | — | — | — | — | — | 1 | |
| Saline spray | — | — | — | — | — | 1 | |
| Weight-based dosing | — | — | — | — | — | 1 | |
| Age-based dosing | — | — | — | — | — | 1 | |
| Application of crisaborole twice daily | — | — | — | — | — | 1 | |
| Tacrolimus ointment in atopic dermatitis | — | — | — | — | — | 1 | |
| intralesional vitamin D3 versus intralesional acyclovir | — | — | — | — | — | 1 | |
| Diacerein | — | — | — | — | — | 1 | |
| Autogenous Demineralized Dentin Graft | — | — | — | — | — | 1 | |
| Autogenous Bone Graft | — | — | — | — | — | 1 | |
| Ephedrine and Norepinephrine | — | — | — | — | — | 1 | |
| Giomer pit and fissure sealant without etching | — | — | — | — | — | 1 | |
| Giomer pit and fissure sealant with etching | — | — | — | — | — | 1 |
223 more active programs hidden
Next readouts
- 2024-05-01
- 2024-06-01
- 2024-08
- 2024-08-15
- 2024-08-30
- 2024-09-01
- 2024-09-01
- 2024-10
- 2024-10-01
- 2024-10-10
Top conditions
- Dental Caries63
- Postoperative Pain50
- Cerebral Palsy45
- Obesity32
- Infertility31
- Low Back Pain30
- Pain26
- Stroke24
Frequently asked questions about Cairo University
- How many clinical trials does Cairo University have on ClinicalTrials.gov?
- Cairo University is listed as the lead sponsor on 4,446 clinical trials in ClinicalTrials.gov, 1,085 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Cairo University's trials are in Phase 3?
- 197 of Cairo University's trials are in Phase 3, spread across 263 active drug programs.
- What therapeutic areas does Cairo University focus on?
- Cairo University's most-studied conditions on ClinicalTrials.gov are Dental Caries, Postoperative Pain, Cerebral Palsy, Obesity, Infertility.
- When are Cairo University's next clinical trial readouts?
- Cairo University has 10 upcoming primary-completion readouts tracked here; the soonest is “Retention Rate of Giomer Pit and Fissure Sealant Applied With or Without Etching”, expected around 2024-05-01.